Abbott, a medical devices and health care company, agreed to acquire Bigfoot Biomedical, a developer of smart insulin management systems for people with diabetes. Financial terms were not disclosed. "The acquisition of Bigfoot Biomedical will combine two leaders in different aspects of diabetes care: continuous glucose monitoring and insulin dosing support. Bringing our companies together will allow us to further develop connected solutions for making diabetes management even more personal and precise," Jared Watkin, Abbott Senior Vice President.